Authors: Lauren Woolfe, Future Science Group
Published today in Infection and Immunity, researchers have identified a novel vaccine for Staphylococcus aureus, which has demonstrated 80% efficacy in mouse and rabbit models.
Hospital-acquired S. aureus infections result in 30,000 deaths annually, with an upper mortality rate of approximately 30%, in cases of bacteremia. With over 70 virulence factors and rapid biofilm formation, S. aureus is highly resistant to the host immune response as well as many antibiotics.
Restricted Content / Members Only
2 Comments
please cite your source
Hi,
The sources are cited at the end of the main article and are as follows:
Harro JM, Achermann Y, Freiberf JA et al. Clearance of Staphylococcus aureus from in vivo models of chronic infection by immunization requires both planktonic and biofilm antigens. Infect. Immun. doi:10.1128/IAI.00586-19 (2019); https://asm.org/Press-Releases/2019/November-1/New-Vaccine-Protects-from-Widespread,-Costly-Infec